Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adverse Drug Reaction Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women

NCT02215395
View directory record Official record
Conditions
Antifungal Drug Adverse Reaction
Interventions
NES/EE CVR
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 13, 2026, 8:51 PM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 13, 2026, 8:51 PM EDT
Recruiting Phase 3 Interventional

Melatonin for Prevention of Kidney Injury

NCT05084196
View directory record Official record
Conditions
Acute Kidney Injury, Adverse Drug Event
Interventions
Melatonin, Placebo Capsule
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 13, 2026, 8:51 PM EDT
Recruiting Phase 2 Interventional

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

NCT06406114
View directory record Official record
Conditions
Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 13, 2026, 8:51 PM EDT
Not listed No phase listed Observational

Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations

NCT04378881
View directory record Official record
Conditions
COVID, Drug Effect, Drug Interaction, Adverse Drug Event
Interventions
Not listed
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Early Phase 1 Interventional

Studies of Sulfur Metabolism in Humans

NCT03383133
View directory record Official record
Conditions
Metabolic Side Effects of Drugs
Interventions
SULT Allosteric Inhibition
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
61 Years to 61 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 13, 2026, 8:51 PM EDT
Withdrawn No phase listed Observational

Implementation of a Pharmacist-led Pharmacogenomic Clinical Service

NCT04984538
View directory record Official record
Conditions
Adverse Drug Event, Drug Drug Interaction, Pharmacogenomics, Elderly
Interventions
Pharmacogenomic Testing
Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 13, 2026, 8:51 PM EDT
Not listed Not applicable Interventional

Improving Geriatric Drug Safety in Underserved Practices

NCT00277173
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Adoption of Crew Resource Management approach
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
65 Years and older
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2006 · Synced Sep 13, 2026, 8:51 PM EDT
Completed No phase listed Observational

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

NCT04770922
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
Up to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Improving Wisely - Polypharmacy

NCT03857100
View directory record Official record
Conditions
Adverse Drug Event
Interventions
Audit and feedback - letter and report
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Not applicable Interventional Results available

Pharmacogenetic Testing Among Home Health Patients

NCT02378220
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Pharmacogenetic testing
Genetic
Lead sponsor
Genelex Corporation
Industry
Eligibility
50 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Searcy, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 13, 2026, 8:51 PM EDT
Completed No phase listed Observational

Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy

NCT04339634
View directory record Official record
Conditions
COVID, Drug Effect, Drug Interaction, Adverse Drug Event
Interventions
Simulation of Repurposed Drugs for COVID-19
Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
55 Years and older
Enrollment
12,873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 13, 2026, 8:51 PM EDT
Terminated Not applicable Interventional Results available

Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions

NCT01600677
View directory record Official record
Conditions
Medication Adherence, Medication Nonadherence, Adverse Reaction to Drug
Interventions
Computerized medication delivery unit, Usual care
Device · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 13, 2026, 8:51 PM EDT
Completed No phase listed Observational

Blood Storage Related Mortality and Adverse Effects in Trauma Patients

NCT07341139
View directory record Official record
Conditions
Transfusion Adverse Reaction, Major Trauma, Blood Product Transfusion for All Conditions
Interventions
Not listed
Lead sponsor
Kocaeli City Hospital
Government
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Not applicable Interventional Results available

Implementation of Real-time ADE Surveillance and Decision Support

NCT00780572
View directory record Official record
Conditions
Adverse Drug Events
Interventions
ADE alert assistant
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 13, 2026, 8:51 PM EDT
Completed No phase listed Observational

Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age

NCT02609919
View directory record Official record
Conditions
Adverse Reaction to Drug, Allergic Reaction to Contrast Media
Interventions
Gadoteric Acid
Drug
Lead sponsor
St. Louis University
Other
Eligibility
Up to 2 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Sep 13, 2026, 8:51 PM EDT
Recruiting Phase 4 Interventional

DESIFOR-EXPAND (MHIF)

NCT06804980
View directory record Official record
Conditions
Statin Therapy, Statin Adverse Reaction, Statin
Interventions
Rosuvastatin (Crestor), Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 13, 2026, 8:51 PM EDT
Recruiting No phase listed Observational

The Texas Interprofessional Pharmacogenomics (IPGx)

NCT06219720
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
50 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Phase 2 Interventional

Statewide Implementation of Electronic Health Records

NCT00225576
View directory record Official record
Conditions
Medication Errors
Interventions
Electronic Health Record Implementation
Other
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Patient Profiling and Provider Feedback to Reduce Adverse Drug Events

NCT00013143
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Patient risk profiling (potential ADEs) w/provider feedback
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

NCT03576469
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
C1-esterase inhibitor [recombinant] (C1-INH-R)
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 13, 2026, 8:51 PM EDT
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 13, 2026, 8:51 PM EDT